A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source: Bloomberg)
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/a077a77ed999dcbc17dad36b20f19d82f35bbf90" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna, Merck Revive mRNA Hopes With Melanoma Success"></iframe>
A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss. (Source: Bloomberg)
